|
US6291425B1
(en)
*
|
1999-09-01 |
2001-09-18 |
Guilford Pharmaceuticals Inc. |
Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
CN100522934C
(zh)
*
|
1999-01-13 |
2009-08-05 |
拜尔有限公司 |
用ω-羧基芳基取代的二苯脲作为raf激酶抑制剂
|
|
US7928239B2
(en)
*
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1690853B1
(en)
*
|
1999-01-13 |
2010-03-10 |
Bayer HealthCare LLC |
Use of omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
WO2000042012A1
(en)
*
|
1999-01-13 |
2000-07-20 |
Bayer Corporation |
φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS
|
|
TR200201364T2
(tr)
|
1999-11-22 |
2002-10-21 |
Smithkline Beecham P. L. C. |
Yeni bileşikler.
|
|
GB0005357D0
(en)
*
|
2000-03-06 |
2000-04-26 |
Smithkline Beecham Plc |
Compounds
|
|
ES2218391T3
(es)
|
2000-03-06 |
2004-11-16 |
Smithkline Beecham Plc |
Derivados de imidazol como inhibidores de raf-cinasa.
|
|
US6645990B2
(en)
|
2000-08-15 |
2003-11-11 |
Amgen Inc. |
Thiazolyl urea compounds and methods of uses
|
|
DE60137273D1
(de)
|
2000-10-20 |
2009-02-12 |
Eisai R&D Man Co Ltd |
Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
|
|
AU2002232439A1
(en)
|
2000-11-29 |
2002-06-11 |
Glaxo Group Limited |
Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
UA76977C2
(en)
|
2001-03-02 |
2006-10-16 |
Icos Corp |
Aryl- and heteroaryl substituted chk1 inhibitors and their use as radiosensitizers and chemosensitizers
|
|
AU2002306618B2
(en)
*
|
2001-03-07 |
2006-11-09 |
Telik, Inc. |
Substituted diarylureas as stimulators for Fas-mediated apoptosis
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
CA2443950C
(en)
*
|
2001-04-20 |
2011-10-18 |
Bayer Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
GB0112348D0
(en)
|
2001-05-19 |
2001-07-11 |
Smithkline Beecham Plc |
Compounds
|
|
WO2003007955A2
(en)
*
|
2001-07-20 |
2003-01-30 |
Cancer Research Technology Limited |
Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
|
|
MXPA04007832A
(es)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aril-ureas con actividad inhibitoria de angiogenesis.
|
|
MXPA04007830A
(es)
*
|
2002-02-11 |
2005-07-01 |
Bayer Pharmaceuticals Corp |
Arilureas como inhibidores de cinasa.
|
|
US10653684B2
(en)
|
2002-02-11 |
2020-05-19 |
Bayer Healthcare Llc |
Aryl ureas with angiogenisis inhibiting activity
|
|
WO2003068229A1
(en)
*
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
TW200406374A
(en)
|
2002-05-29 |
2004-05-01 |
Novartis Ag |
Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
|
|
WO2004012733A2
(en)
*
|
2002-08-01 |
2004-02-12 |
Neurosearch A/S |
Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
|
|
US7056925B2
(en)
|
2002-08-13 |
2006-06-06 |
Abbott Laboratories |
Urea kinase inhibitors
|
|
US20040034038A1
(en)
*
|
2002-08-13 |
2004-02-19 |
Goaquan Li |
Urea kinase inhibitors
|
|
CA2511970C
(en)
|
2003-01-14 |
2012-06-26 |
Cytokinetics, Inc. |
Urea derivatives useful in the treatment of heart failure
|
|
EP1603879A2
(en)
*
|
2003-02-28 |
2005-12-14 |
Bayer Pharmaceuticals Corporation |
Substituted pyridine derivatives useful in the treatment of cancer and other disorders
|
|
EP1608639A2
(en)
|
2003-02-28 |
2005-12-28 |
Bayer Pharmaceuticals Corporation |
Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders
|
|
MXPA05012377A
(es)
|
2003-05-15 |
2006-05-25 |
Arqule Inc |
Derivados de imidazotiazoles e imidazoxazol como inhibidores de p38.
|
|
WO2004113274A2
(en)
|
2003-05-20 |
2004-12-29 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas with kinase inhibiting activity
|
|
PT1558582E
(pt)
|
2003-07-22 |
2006-05-31 |
Arena Pharm Inc |
Derivados de diaril- e aril-heteroaril-ureia como moduladores do receptor de serotonina 5-ht2a uteis para a profilaxia e tratamento de desordens relacionadas com o mesmo
|
|
EA010485B1
(ru)
|
2003-07-23 |
2008-10-30 |
Байер Фамэсьютиклс Копэрейшн |
Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
|
|
DE10334663A1
(de)
*
|
2003-07-30 |
2005-03-10 |
Merck Patent Gmbh |
Harnstoffderivate
|
|
US7683172B2
(en)
|
2003-11-11 |
2010-03-23 |
Eisai R&D Management Co., Ltd. |
Urea derivative and process for preparing the same
|
|
US20070161677A1
(en)
*
|
2004-01-30 |
2007-07-12 |
Merck Patent Gmbh |
Bisarylurea derivatives
|
|
TW200530236A
(en)
|
2004-02-23 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Heteroaryl phenylurea
|
|
CA2559038C
(en)
|
2004-03-23 |
2013-09-10 |
Arena Pharmaceuticals, Inc. |
Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl) phenyl] ureas and intermediates thereof
|
|
CN101010315A
(zh)
|
2004-04-30 |
2007-08-01 |
拜耳制药公司 |
用于治疗癌症的取代的吡唑基脲衍生物
|
|
JP5080970B2
(ja)
|
2004-06-17 |
2012-11-21 |
サイトキネティクス・インコーポレーテッド |
心疾患を治療するための置換尿素誘導体
|
|
RS56037B1
(sr)
|
2004-06-24 |
2017-09-29 |
Vertex Pharma |
Modulatori atp-vezujućih kasetnih transportera
|
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
|
JP2008505112A
(ja)
*
|
2004-07-02 |
2008-02-21 |
イコス・コーポレイション |
Ｃｈｋ１の阻害に有用な化合物
|
|
WO2006010082A1
(en)
|
2004-07-08 |
2006-01-26 |
Arqule, Inc. |
1,4-disubstituted naphtalenes as inhibitors of p38 map kinase
|
|
AU2005272586A1
(en)
*
|
2004-08-19 |
2006-02-23 |
Icos Corporation |
Compounds useful for inhibiting CHK1
|
|
MY191349A
(en)
*
|
2004-08-27 |
2022-06-17 |
Bayer Pharmaceuticals Corp |
New pharmaceutical compositions for the treatment of hyper-proliferative disorders
|
|
AU2005283422C1
(en)
|
2004-09-17 |
2017-02-02 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
|
CA2584185C
(en)
|
2004-10-13 |
2014-07-15 |
Frank Stieber |
Heterocyclic substituted bisarylurea derivates as kinase inhibitors
|
|
JP2008517064A
(ja)
|
2004-10-19 |
2008-05-22 |
アークル インコーポレイテッド |
Ｐ３８ｍａｐキナーゼのイミダゾオキサゾールおよびイミダゾチアゾール阻害剤の合成
|
|
SA05260357B1
(ar)
|
2004-11-19 |
2008-09-08 |
ارينا فارماسيتو تيكالز ، أنك |
مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
|
|
WO2006076592A1
(en)
|
2005-01-14 |
2006-07-20 |
Cgi Pharmaceuticals, Inc. |
1,3 substituted diaryl ureas as modulators of kinase activity
|
|
RU2402544C2
(ru)
*
|
2005-01-14 |
2010-10-27 |
Си Джи Ай ФАРМАСЬЮТИКАЛЗ, ИНК. |
1,3-диарилзамещенные мочевины как модуляторы киназной активности
|
|
SG160364A1
(en)
|
2005-03-07 |
2010-04-29 |
Bayer Schering Pharma Ag |
Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
|
|
WO2007024294A2
(en)
|
2005-05-03 |
2007-03-01 |
Cgi Pharmaceuticals, Inc. |
Certain substituted ureas, as modulators of kinase activity
|
|
WO2007015578A1
(ja)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
血管新生阻害物質の効果を検定する方法
|
|
US7538223B2
(en)
|
2005-08-04 |
2009-05-26 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
JP5072595B2
(ja)
|
2005-08-05 |
2012-11-14 |
中外製薬株式会社 |
マルチキナーゼ阻害剤
|
|
US7825120B2
(en)
|
2005-12-15 |
2010-11-02 |
Cytokinetics, Inc. |
Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
|
|
TW200808321A
(en)
|
2005-12-15 |
2008-02-16 |
Cytokinetics Inc |
Certain chemical entities, compositions and methods
|
|
EP1959962A2
(en)
|
2005-12-16 |
2008-08-27 |
Cytokinetics, Inc. |
Certain chemical entities, compositions, and methods
|
|
EP1962852B1
(en)
|
2005-12-19 |
2017-01-25 |
Cytokinetics, Inc. |
Compounds, compositions and methods
|
|
EP3219705B1
(en)
|
2005-12-28 |
2020-03-11 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
|
JP5286254B2
(ja)
|
2006-05-18 |
2013-09-11 |
アリーナ ファーマシューティカルズ， インコーポレイテッド |
５−ｈｔ２ａセロトニンレセプター活性のモジュレーターとして有用なフェニルピラゾールの結晶形態および調製方法
|
|
CA2646076C
(en)
|
2006-05-18 |
2015-06-30 |
Arena Pharmaceuticals, Inc. |
Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
ES2536762T3
(es)
|
2006-05-18 |
2015-05-28 |
Arena Pharmaceuticals, Inc. |
Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este
|
|
RU2448708C3
(ru)
|
2006-05-18 |
2017-09-28 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Противоопухолевое средство против рака щитовидной железы
|
|
US20080045589A1
(en)
|
2006-05-26 |
2008-02-21 |
Susan Kelley |
Drug Combinations with Substituted Diaryl Ureas for the Treatment of Cancer
|
|
CN101511793B
(zh)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
针对未分化型胃癌的抗肿瘤剂
|
|
TWI415845B
(zh)
|
2006-10-03 |
2013-11-21 |
Arena Pharm Inc |
用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
|
|
WO2008044688A1
(en)
*
|
2006-10-11 |
2008-04-17 |
Daiichi Sankyo Company, Limited |
Urea derivative
|
|
JP2010514692A
(ja)
|
2006-12-20 |
2010-05-06 |
バイエル ヘルスケア リミティド ライアビリティ カンパニー |
癌の治療に有用なヒドロキシメチルフェニルピラゾリル尿素化合物
|
|
CN101600694A
(zh)
|
2007-01-29 |
2009-12-09 |
卫材R&D管理有限公司 |
未分化型胃癌治疗用组合物
|
|
EP2136809A4
(en)
*
|
2007-03-20 |
2012-01-04 |
Curis Inc |
INHIBITORS OF RAF KINASE CONTAINING A ZINC BINDING FRAGMENT
|
|
WO2009023253A2
(en)
|
2007-08-15 |
2009-02-19 |
Arena Pharmaceuticals Inc. |
IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
|
|
WO2009035949A2
(en)
*
|
2007-09-13 |
2009-03-19 |
Arete Therapeutics, Inc. |
Soluble epoxide hydrolase inhibitors
|
|
KR101513326B1
(ko)
|
2007-11-09 |
2015-04-17 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
혈관 신생 저해 물질과 항종양성 백금 착물의 병용
|
|
AU2008337286B2
(en)
*
|
2007-12-19 |
2014-08-07 |
Cancer Research Technology Limited |
Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
|
|
PE20091561A1
(es)
|
2008-02-29 |
2009-10-30 |
Array Biopharma Inc |
Compuestos inhibidores de raf y metodos para su uso
|
|
JP2011513331A
(ja)
|
2008-02-29 |
2011-04-28 |
アレイ バイオファーマ、インコーポレイテッド |
ピラゾール［３，４−ｂ］ピリジンＲＡＦ阻害剤
|
|
CN101372475B
(zh)
*
|
2008-03-19 |
2012-01-04 |
南京工业大学 |
芳杂环取代的二苯脲类衍生物及其用途
|
|
WO2009123714A2
(en)
|
2008-04-02 |
2009-10-08 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
|
|
US12458635B2
(en)
|
2008-08-13 |
2025-11-04 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
|
WO2010062321A1
(en)
|
2008-10-28 |
2010-06-03 |
Arena Pharmaceuticals, Inc. |
Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
|
|
CN104739829B
(zh)
|
2008-10-28 |
2018-11-06 |
艾尼纳制药公司 |
用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
|
|
PL2408750T3
(pl)
|
2009-03-20 |
2016-02-29 |
Vertex Pharma |
Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
|
|
DK2468281T3
(en)
|
2009-08-19 |
2016-03-21 |
Eisai R&D Man Co Ltd |
Quinolinderivatholdig pharmaceutical composition
|
|
EP2470022A4
(en)
*
|
2009-08-28 |
2014-08-06 |
Glaxosmithkline Llc |
COMPOUNDS AND METHODS
|
|
WO2011075596A1
(en)
|
2009-12-18 |
2011-06-23 |
Arena Pharmaceuticals, Inc. |
Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
|
|
WO2011162343A1
(ja)
|
2010-06-25 |
2011-12-29 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤
|
|
CA2805874A1
(en)
|
2010-07-19 |
2012-01-26 |
Bayer Healthcare Llc |
Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
|
CN102134207B
(zh)
*
|
2011-01-14 |
2013-04-17 |
厦门大学 |
一种脲化合物及其制备方法和用途
|
|
CN103402519B
(zh)
|
2011-04-18 |
2015-11-25 |
卫材R&D管理有限公司 |
肿瘤治疗剂
|
|
JP6038128B2
(ja)
|
2011-06-03 |
2016-12-07 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
|
|
CA2843330C
(en)
*
|
2011-08-03 |
2016-09-20 |
National Taiwan University |
Substituted phenyl- and heteroaryl-phenyl ether agonists of src homology-2 containing protein tyrosine phosphatase-1 and treatment methods using the same
|
|
JP2015511583A
(ja)
|
2012-02-27 |
2015-04-20 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
薬学的組成物およびその投与
|
|
AU2013364953A1
(en)
|
2012-12-21 |
2015-04-30 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
|
EP2997377B1
(en)
|
2013-05-14 |
2018-07-18 |
Eisai R&D Management Co., Ltd. |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
|
EP3046557A1
(en)
|
2013-09-20 |
2016-07-27 |
Stichting Het Nederlands Kanker Instituut |
Rock in combination with mapk-pathway
|
|
WO2015041534A1
(en)
|
2013-09-20 |
2015-03-26 |
Stichting Het Nederlands Kanker Instituut |
P90rsk in combination with raf/erk/mek
|
|
US20170027940A1
(en)
|
2014-04-10 |
2017-02-02 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
|
WO2015178770A1
(en)
|
2014-05-19 |
2015-11-26 |
Stichting Het Nederlands Kanker Instituut |
Compositions for cancer treatment
|
|
RU2743074C2
(ru)
|
2014-08-01 |
2021-02-15 |
Нуэволюшон А/С |
Соединения, активные по отношению к бромодоменам
|
|
PT3524595T
(pt)
|
2014-08-28 |
2022-09-19 |
Eisai R&D Man Co Ltd |
Derivado de quinolina altamente puro e método para produção do mesmo
|
|
CN107250113B
(zh)
|
2014-10-07 |
2019-03-29 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调节蛋白的调节剂的共晶
|
|
US9638690B2
(en)
|
2014-11-07 |
2017-05-02 |
The University Of British Columbia |
Compounds and compositions for use as alkylating agent sensors and methods of use thereof
|
|
AU2016224583B2
(en)
|
2015-02-25 |
2021-06-03 |
Eisai R&D Management Co., Ltd. |
Method for suppressing bitterness of quinoline derivative
|
|
KR102662228B1
(ko)
|
2015-03-04 |
2024-05-02 |
머크 샤프 앤드 돔 코포레이션 |
암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
|
|
CN104817493A
(zh)
*
|
2015-03-11 |
2015-08-05 |
西安交通大学 |
一种芳杂环酰胺取代的二芳基脲化合物及其制备方法和应用
|
|
CN104744350A
(zh)
*
|
2015-03-11 |
2015-07-01 |
西安交通大学 |
一种吡啶取代的二芳基脲化合物及其制备方法和应用
|
|
WO2016201373A1
(en)
|
2015-06-12 |
2016-12-15 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
|
|
BR112017027227B1
(pt)
|
2015-06-16 |
2023-12-12 |
Eisai R&D Management Co., Ltd |
Agente anti-câncer
|
|
WO2017011767A2
(en)
|
2015-07-15 |
2017-01-19 |
Axovant Sciences Ltd. |
Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
|
|
CN107922375B
(zh)
*
|
2015-07-30 |
2020-05-22 |
正大天晴药业集团股份有限公司 |
靶向idh2突变的抗肿瘤化合物及其使用方法
|
|
JP6553726B2
(ja)
|
2015-08-20 |
2019-07-31 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療剤
|
|
JP6581320B2
(ja)
|
2017-02-08 |
2019-09-25 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
腫瘍治療用医薬組成物
|
|
EP3624800A4
(en)
|
2017-05-16 |
2021-02-17 |
Eisai R&D Management Co., Ltd. |
TREATMENT OF HEPATOCELLULAR CARCINOMA
|
|
CN108997209B
(zh)
*
|
2018-06-11 |
2020-08-04 |
山东罗欣药业集团恒欣药业有限公司 |
一种瑞戈非尼的制备方法
|
|
MA52954A
(fr)
*
|
2018-06-21 |
2021-04-28 |
Cellestia Biotech Ag |
Procédé pour la fabrication d'aminoéthers de diaryle et sels de chlorhydrate d'aminoéthers de diaryle
|
|
CN110128299B
(zh)
*
|
2019-05-13 |
2020-11-10 |
浙江大学 |
一种二苯基脲类抗肿瘤小分子抑制剂及其制备方法
|
|
CN113121484A
(zh)
|
2019-12-31 |
2021-07-16 |
复星弘创(苏州)医药科技有限公司 |
一种制备3-位被酰胺基烷基取代的香豆素类化合物的方法及其产物和相关中间体
|
|
KR102770474B1
(ko)
*
|
2021-03-23 |
2025-02-21 |
한국과학기술연구원 |
신규한 화합물 및 이를 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
|